Pharmacovigilance Consulting Services

Cisema supports pharmaceutical companies with end-to-end pharmacovigilance (PV) services tailored to the evolving regulatory environment in China and the Asia Pacific region. We help you establish, maintain, and optimize pharmacovigilance systems that align with local requirements, including those of the NMPA in China, and global best practices, from clinical development through post-marketing surveillance.

We combine regional insight with global expertise to ensure regulatory compliance, reduce adverse event risk, and uphold patient safety. Whether entering the Chinese market or expanding throughout Asia Pacific, our tailored consulting services cover the full range of pharmacovigilance activities required to manage drug safety, maintain product licenses, and ensure compliance with evolving regulatory guidelines.

Pharmacovigilance Consulting Services
Pharmacovigilance Consultants

Our Pharmacovigilance Consulting Services in China & Asia Pacific

Signal Management

Early identification and evaluation of safety signals is essential in the dynamic regulatory environment of China and Asia Pacific. We offer robust signal detection solutions supported by localized knowledge and up to date interpretation of regulatory authorities' expectations.

Risk Management Plans (RMPs)

We assist in the development and localization of RMPs in line with both Chinese and regional regulatory requirements and industry best practices. Our approach to risk management ensures that your products retain a positive safety profile across all relevant markets.

Individual Case Safety Report (ICSR) Management

Our team handles the end-to-end lifecycle of ICSRs, including the intake of adverse event information, case processing, assessment, and submission. We ensure timely and accurate safety reporting in accordance with China’s NMPA and other Asia Pacific regulatory authorities, including strict local timelines and formats.

Clinical Trial Safety Monitoring

We provide end-to-end pharmacovigilance services for clinical trials, including serious adverse event monitoring, safety data analysis, and regulatory liaison. Our services help maintain patient safety and ensure that your clinical trials progress without regulatory delays.

PV System Audits & CAPA

Our audits assess your pharmacovigilance system against local and global standards. We help implement standard operating procedures, work instructions, and CAPAs to strengthen your pharmacovigilance operations and reduce the risk of non-compliance. We help ensure ongoing inspection readiness and regulatory conformity across multiple Asia Pacific jurisdictions.

Post-Marketing Surveillance

Cisema offers real-world safety monitoring and reporting to ensure long-term drug safety and compliance after product launch. Our post marketing surveillance services include managing periodic safety update reports, tracking emerging adverse effects, and ensuring timely reporting to regulatory authorities.

Qualified Person for Pharmacovigilance (QPPV) Services

We provide qualified person for pharmacovigilance (QPPV) services in China and select Asia Pacific markets, ensuring that your pharmacovigilance systems remain compliant, fully documented, and audit-ready, including the preparation of a pharmacovigilance system master file.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Frequently Asked Questions

Our pharmacovigilance consulting includes support across the full product lifecycle, from clinical trial design to post marketing surveillance, ensuring effective safety operations, audit readiness, and compliance with local and global requirements.

Yes. We manage trial safety oversight, including SAE reporting and safety data analysis, in compliance with country-specific requirements throughout China and Asia Pacific.

We prepare and submit Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) in accordance with local regulatory requirements across the region.

Yes. We provide qualified person (QPPV) and responsible person services in China and select Asia Pacific markets, ensuring local oversight and regulatory communication with regulatory authorities.

Varying regulatory requirements, language barriers, and local compliance obligations create complexity. We guide clients through country-specific expectations, supporting robust pharmacovigilance operations that meet regulatory and industry standards.

We document, assess, and report adverse events and serious adverse events in compliance with national regulatory authorities, reducing risk and supporting ongoing regulatory compliance.

Yes. Our post-marketing surveillance services cover multiple Asia Pacific jurisdictions, helping you meet ongoing safety obligations with real-world data analysis and regional reporting expertise.

We conduct gap analyses and implement CAPAs to restore regulatory compliance and mitigate the risk of enforcement actions across jurisdictions in China and Asia Pacific.

Our pharmacovigilance consultants bring deep regional and technical expertise, reducing your internal workload and enhancing compliance across pharmaceutical products in Asia Pacific.

We offer ongoing support, training, and audits to help your pharmacovigilance systems evolve in line with regulatory changes and emerging drug safety concerns, and the latest industry developments.

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Angebot anfordern

Explore Related Services

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Mehr erfahren

Pharmaceutical Development & Strategy

Drive successful market entry and growth with confidence. Our pharmaceutical regulatory consulting experts support biotech and life sciences companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Mehr erfahren

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Mehr erfahren

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Mehr erfahren

Aktuelle Einblicke

Mehr anzeigen

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing

China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services

China's 2026 enforcement priorities expand scrutiny of pharmaceutical sales, procurement, pricing, data security, and compliance across the healthcare sector.

August 3, 2026
China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services
Zurück
Zurück

Get in Touch with Our Pharma Consultants

Speak with our specialists to explore how our PV, regulatory and operational support can help your company succeed in the region’s evolving market access landscape.

Angebot anfordern